MANIFOLD
Date first peer reviewed manuscript in Cell, Nature, or Science concludes SARS2 lab origin more likely than not
39
Ṁ3.6kṀ4.9k
resolved Feb 12
74%70%
Never or on/after 1/1/2029
26%24%
1/1/2027 - 12/31/2028
0.9%
Before 2025
4%
1/1/2025 - 12/31/2026

The reference date is the date a peer reviewed manuscript first appears online at the journal website or is otherwise published by any of these three journals after being accepted for publication. Any peer reviewed manuscript type is acceptable. If lab leak likelihood is generally accepted based on data and analysis elsewhere, inevitably this will be cited approvingly in a peer reviewed manuscript in one of these journals shortly thereafter.

Any statement equivalent to finding over 50% likelihood for SARS-CoV-2 originating in a laboratory that reflects author(s) conclusions and is published following peer review qualifies.

In the vanishingly unlikely event anyone asks, I will refuse to comment on potentially qualifying manuscripts in submission.

While this is the most objective question I could come up with to address this point, I will not participate in the market.

Market context
Get
Ṁ1,000
to start trading!

🏅 Top traders

#TraderTotal profit
1Ṁ156
2Ṁ98
3Ṁ48
4Ṁ38
5Ṁ35
Sort by:

2025 has ended and now the first two options are scheduled to eventually resolve no.

If current holders prefer, I can resolve the last two options to their current values rather than wait until 2029. Easier for me. The other version of this question is better.

@zcoli Resolved this -- check out the other question.

Here's a set version @Gameknight

bought Ṁ741 NO

@zcoli Can you resolve the Before 2025 option?

@Gameknight Someone can make a related market on how long it will take me to figure out how to do that. On my phone I can resolve for 3 out of 4 but I think this closes the market and pays out? I will take a look later today and figure it out.

@zcoli appears to not be a me problem — https://manifold.markets/FlorisvanDoorn/when-will-manifold-markets-allow-us?play=true

@zcoli FYI I plan to resolve individual choices asap when/if it becomes possible.

@zcoli Got it. I thought this was a Set question. Set is basically a better version of Multiple Choice. You can still choose to only resolve one option as YES (in the case that all options are mutually exclusive), but Set allows you to resolve any individual choice at any time.

@Gameknight thanks for the tip -- hopefully I did it correctly here https://manifold.markets/zcoli/which-scientists-featured-in-thank

@zcoli Yeah, probably? Multiple choice is good in that it spreads out probability for a sum total of 100% across all choices, but at the same time it also prevents individual resolving, which definitely feels like an oversight that the devs should try to fix. Set on the other hand is great for individual resolving, but also isn't really probabilistically correct - the sum can be over 100%.

@Gameknight it’s now possible to resolve fractionally to different outcomes so I can do that (resolve to zero for 2024 and 2025; resolve other two at current price) if folks want. I prefer it.

very interesting how this market trades with the /IsaacKing/did-covid19-come-from-a-laboratory at 75%+ for so long

@firstuserhere Does the difference reflects buying to send different signals in one or both markets or a collective belief that these journals won't publish well supported conclusions for some reason? Beats me.

It's good to see someone finally buy "No" on "Never or not for a long time" by the way. This isn't a particularly high bar as these journals publish things that seem likely to be retracted and ultimately are retracted now and then. And PNAS and eLife have shown that fairly high profile journals will entertain controversial points of view on the question.

© Manifold Markets, Inc.TermsPrivacy